• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预防和治疗新型冠状病毒肺炎的起源、结构特征、预防措施、诊断及潜在药物。 (你原文中“to prevent and COVID-19”表述有误,推测可能是“to prevent and treat COVID-19”,我按纠正后的意思翻译了,若有误请指出)

Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.

作者信息

Santos-Sánchez Norma Francenia, Salas-Coronado Raúl

机构信息

Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. ORCID: 0000-0001-5094-0488.

Instituto de Agroindustrias, Universidad Tecnológica de la Mixteca, Huajuapan de León, Oaxaca, México. Dirección: km 2,5 Huajuapan de León, Oaxaca, México, Código postal: 69000. Email:

出版信息

Medwave. 2020 Sep 25;20(8):e8037. doi: 10.5867/medwave.2020.08.8037.

DOI:10.5867/medwave.2020.08.8037
PMID:33017386
Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发2019冠状病毒病(COVID-19)。2019年12月在中国武汉市发现了这种疾病。感染COVID-19的人表现出不同的症状,这取决于他们的健康状况和年龄。最常见的症状是发热、咳嗽、肌痛、疲劳、吞咽痛和呼吸困难。60岁以上的感染成年人是最易患严重COVID-19状态的患者群体,并且在患有慢性病时会出现合并症。另一方面,进行检测以在人群中检测SARS-CoV-2并快速、可靠且廉价地跟踪COVID-19的演变情况也很重要。为此,有实时逆转录聚合酶链反应(RT-PCR)检测、等温核酸扩增和酶免疫刺激检测。目前,尚无预防感染和对抗病毒作用的药物治疗方法。然而,不同的研究小组正在进行体外、体内和计算机模拟试验,以寻找能够提供免疫反应并控制人类感染SARS-CoV-2的药物。氯喹、羟氯喹、瑞德西韦、干扰素α2b和奥司他韦是在预防COVID-19的临床试验中评估的一些药理学选择。本综述的目的是建立一个参考框架,用于SARS-CoV-2的分类学分类及其与其他冠状病毒的关系,以及它们在人体内的结构和传播途径。还介绍了COVID-19患者呈现的特征和症状、检测方法以及可能的治疗方法。

相似文献

1
Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.预防和治疗新型冠状病毒肺炎的起源、结构特征、预防措施、诊断及潜在药物。 (你原文中“to prevent and COVID-19”表述有误,推测可能是“to prevent and treat COVID-19”,我按纠正后的意思翻译了,若有误请指出)
Medwave. 2020 Sep 25;20(8):e8037. doi: 10.5867/medwave.2020.08.8037.
2
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
3
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征,以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
4
The epidemiology, diagnosis and treatment of COVID-19.新型冠状病毒肺炎的流行病学、诊断与治疗。
Int J Antimicrob Agents. 2020 May;55(5):105955. doi: 10.1016/j.ijantimicag.2020.105955. Epub 2020 Mar 28.
5
COVID-19 diagnosis and management: a comprehensive review.COVID-19 的诊断与管理:全面综述。
J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.
6
Outbreak of COVID-19: An emerging global pandemic threat.新型冠状病毒疫情:新兴的全球大流行病威胁。
Biomed Pharmacother. 2020 Sep;129:110499. doi: 10.1016/j.biopha.2020.110499. Epub 2020 Jul 4.
7
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病(COVID-19)后成年人暴露者预防严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的暴露后预防效果:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
8
Recent progress on the diagnosis of 2019 Novel Coronavirus.新型冠状病毒诊断的最新进展。
Transbound Emerg Dis. 2020 Jul;67(4):1485-1491. doi: 10.1111/tbed.13620. Epub 2020 May 31.
9
The race against COVID-19.与新冠病毒的赛跑。
Nat Nanotechnol. 2020 Apr;15(4):239-240. doi: 10.1038/s41565-020-0680-y.
10
Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020.2020 年 1 月至 2 月期间,中国武汉一家医院对 4880 例病例进行的 SARS-CoV-2 感染的 RT-PCR 检测阳性率。
Clin Chim Acta. 2020 Jun;505:172-175. doi: 10.1016/j.cca.2020.03.009. Epub 2020 Mar 7.

引用本文的文献

1
Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers.灭活严重急性呼吸综合征冠状病毒2(Vero细胞)疫苗在秘鲁医护人员中的有效性。
Life (Basel). 2022 Aug 26;12(9):1318. doi: 10.3390/life12091318.
2
Defense of COVID-19 by Human Organoids.人类类器官对新冠病毒的防御作用
Phenomics. 2021;1(3):113-128. doi: 10.1007/s43657-021-00015-0. Epub 2021 Jul 14.